Olanzapine — Atypical antipsychotic. Study the mechanism, listed uses and warnings from the US label on one sourced card.
Generic name
Olanzapine
Class
Atypical antipsychotic
Mechanism
Mechanism is unclear; efficacy in schizophrenia may involve combined dopamine and serotonin 5-HT2 antagonism.
Used for
Schizophrenia in adults and adolescents aged 13–17 years; Acute manic or mixed episodes of bipolar I disorder in adults and adolescents aged 13–17 years; maintenance treatment in adults; Adjunct to lithium or valproate for acute manic or mixed episodes of bipolar I disorder in adults
Increased mortality in elderly patients with dementia-related psychosis.
Warnings
Hyperglycemia / diabetes; Dyslipidemia and weight gain; Cerebrovascular events in elderly dementia
Interactions
Diazepam / alcohol; Carbamazepine; Fluvoxamine
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260908 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: Mechanism is unclear; activity in schizophrenia may involve combined dopamine D2 and serotonin 5-HT2 receptor antagonism.
On both cards: Used for — Schizophrenia in adults and adolescents aged 13–17 years · Common side effects — Dizziness
Only on the Risperidone card: Used for — Acute manic or mixed episodes of bipolar I disorder: monotherapy in adults and patients aged 10–17 years, or adjunct to lithium or valproate in adults; Irritability associated with autistic disorder in patients aged 5–17 years · Common side effects — Parkinsonism; Akathisia; Sedation; Increased weight · Warnings — Neuroleptic malignant syndrome; Tardive dyskinesia; Metabolic changes · Interactions — Carbamazepine / enzyme inducers; Fluoxetine / paroxetine (CYP2D6 inhibitors)
Mechanism: Mechanism unclear; efficacy may be mediated by combined dopamine D2 and serotonin 5-HT2 receptor antagonism.
On both cards: Common side effects — Weight gain; Somnolence; Dizziness; Constipation; Dry mouth · Warnings — Cerebrovascular events in elderly dementia
Only on the Quetiapine card: Used for — Schizophrenia in adults and adolescents aged 13 years and older; Acute bipolar I mania as monotherapy in adults and children aged 10 years and older, or as adjunct to lithium/divalproex in adults; Acute bipolar depressive episodes as monotherapy in adults · Warnings — Neuroleptic malignant syndrome; Hyperglycemia, dyslipidemia, weight gain · Interactions — Strong CYP3A4 inhibitors (ketoconazole, ritonavir); Strong CYP3A4 inducers (phenytoin, rifampin)
Mechanism: Exact mechanism unknown; believed to potentiate serotonergic and noradrenergic activity in the CNS.
On both cards: Common side effects — Somnolence; Constipation; Dry mouth
Only on the Duloxetine card: Used for — Major depressive disorder in adults; Generalized anxiety disorder in adults and children aged 7 years and older; Diabetic peripheral neuropathic pain in adults; Fibromyalgia in adults and adolescents aged 13 years and older; Chronic musculoskeletal pain in adults · Common side effects — Nausea; Hyperhidrosis · Warnings — Hepatotoxicity; Orthostatic hypotension, falls, syncope; Serotonin syndrome · Interactions — Potent CYP1A2 inhibitors; Potent CYP2D6 inhibitors; MAOIs
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Capsera